Investigating Serotonin Signalling in IBD Patients (IBD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01650311|
Recruitment Status : Recruiting
First Posted : July 26, 2012
Last Update Posted : September 2, 2020
|Condition or disease|
|Inflammatory Bowel Disease|
The gut produces approximately 95% of serotonin (5-hydroxytryptamine; 5-HT) found in the human body; where, it is a very important mucosal signaling molecule participating in gut motility, sensation, and secretion.The vast majority of the gut-derived 5-HT is produced by specialized epithelial cells of The GI tract, called enterochromaffin (EC) cells. EC cells produce 5-HT from dietary tryptophan, this process involves the rate limiting enzyme tryptophan hydroxylase (TPH) 1, once produced this 5-HT can be released into the gut lumen, surrounding tissue and can enter the blood circulation.5-HT mediates many gastrointestinal functions, including secretion and peristalsis, by acting on a diverse range of 5-HT receptors. Five of the seven known receptor families of 5-HT (5-HT1, 5-HT2, 5-HT3, 5-HT4 and 5-HT7) are expressed in the gut.
5-HT has been evaluated in IBD and in animal models of colitis. An increase in numbers of EC cells expressing 5-HT is observed in CD and UC patients and consumption of selective 5-HT reuptake inhibitors is associated with microscopic colitis. In the present study, we plan to investigate the key elements of mucosal 5-HT signaling in CD patients for a better understanding of the role of 5-HT in pathogenesis of IBD.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Investigating Serotonin Signalling in IBD Patients|
|Study Start Date :||July 2012|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2021|
Healthy control group will include participants consenting prior to colorectal cancer screening.
CD patient groups
The patient groups will include patients with clinical diagnosis of CD.
UC patient group
The patient groups will include patients with clinical diagnosis of UC.
- TPH1 and SERT expression [ Time Frame: At the time of sample collection ]
- Receptor expressions [ Time Frame: At the time of sample collection ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01650311
|Contact: Md. Sharif Shajib, BSc.||905-525-9140 ext email@example.com|
|Contact: Janice Kim, PhD.||905-525-9140 ext firstname.lastname@example.org|
|McMaster University Medical Center||Recruiting|
|Hamilton, Ontario, Canada, L8S 4K1|
|Principal Investigator:||Waliul I Khan, MBBS, PhD.||Dept. of Pathology & Molecular Medicine, McMaster University, Hamilton, Canada.|
|Principal Investigator:||John Marshall, MD, MSc, FRCPC, AGAF.||Department of Medicine, McMaster University, Hamilton, Canada.|